Lysine

BLOOD AND BLOOD FORMING ORGANS

Key facts

Lysine is an ofp drug catalogued in DrugCentral. It was first approved by the EMA in 2019. DrugCentral lists 1 molecular target, including GSR. Recorded indications include Partial Central Diabetes Insipidus and Renal radiation exposure from Lutetium (177Lu) oxodotreotide.

• Approval status: ofp (first approved 2019 by the EMA).
• Molecular targets: GSR (1 listed in DrugCentral).
• Indications: Partial Central Diabetes Insipidus and Renal radiation exposure from Lutetium (177Lu) oxodotreotide.
• ATC code: B05XB03 (Amino acids).
• Molecular formula: C6H14N2O2; molecular weight 146.19 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (2)

• Partial Central Diabetes Insipidus
• Renal radiation exposure from Lutetium (177Lu) oxodotreotide

Contraindications (11)

• Classical phenylketonuria
• End stage renal disease
• Heart disease
• Humoral hypercalcemia of malignancy
• Hypercalcemia
• Hypercalciuria
• Kidney disease
• Kidney stone
• Poisoning by digitalis glycoside
• Sarcoidosis
• Ventricular fibrillation

Mechanism & targets

Molecular targets (1)

Target	Gene	Action	Activity
Glutathione reductase, mitochondrial	GSR	unknown	Ki 4.26

Regulatory approvals (3)

Date	Agency	Marketed as	Applicant	Orphan
2021-06-23	PMDA	—	FUJIFILM TOYAMA CHEMICAL Co., Ltd.
2019-07-25	EMA	—	Advanced Accelerator Applications
—	FDA	—	—

ATC classification

ATC code	Therapeutic hierarchy
B05XB03	BLOOD AND BLOOD FORMING ORGANS › BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS › I.V. SOLUTION ADDITIVES › Amino acids
V03AF11	VARIOUS › ALL OTHER THERAPEUTIC PRODUCTS › ALL OTHER THERAPEUTIC PRODUCTS › Detoxifying agents for antineoplastic treatment

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Therapy cessation	191.3
Toxicity to various agents	150.8
Electric shock	143.2
Hand deformity	139.2
Treatment failure	132.7
Pemphigus	131.6
Blood uric acid increased	128.7
Systemic lupus erythematosus	125.4
Macular degeneration	123.3
Constipation	119.4
Off label use	118.1
Low turnover osteopathy	109.4

Chemical structure

Full physicochemical, ADMET and 3D-structure analysis of Lysine is on its molecule page.

• Molecular formula: C₆H₁₄N₂O₂
• Molecular weight: 146.19 g/mol
• CAS number: —
• InChIKey: KDXKERNSBIXSRK-YFKPBYRVSA-N
• PubChem CID: 5962

NCCCC[C@H](N)C(O)=O

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Lysine used for?

DrugCentral lists the following indications for Lysine: Partial Central Diabetes Insipidus and Renal radiation exposure from Lutetium (177Lu) oxodotreotide.

How does Lysine work?

Its molecular targets in DrugCentral include GSR.

When was Lysine first approved?

Lysine was first approved by the EMA in 2019.

What is the chemical formula of Lysine?

Lysine has the molecular formula C6H14N2O2 and a molecular weight of 146.19 g/mol.

Sources

• DrugCentral drug card 1622 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL2105886 — compound record and bioactivity
• PubChem CID 5962 — chemical identifiers
• DrugBank DB00123 — drug record
• FDA UNII K3Z4F929H6 — substance identity
• DailyMed: FDA labels for Lysine — current prescribing information (label search)
• UniProt P00390 (GSR) — target protein
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral

How this page is built: methodology · editorial policy & corrections.